ABBV - AbbVie Inc.

NYSE - NYSE Delayed Price. Currency in USD
88.91
-1.04 (-1.16%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close89.95
Open0.00
Bid86.29 x 100
Ask92.75 x 2000
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume8,457,166
Market Cap134.615B
Beta1.67
PE Ratio (TTM)22.36
EPS (TTM)3.98
Earnings DateJul 27, 2018
Forward Dividend & Yield3.84 (3.96%)
Ex-Dividend Date2018-07-12
1y Target Est113.05
Trade prices are not sourced from all markets
  • The Global Cannabis Market Is Set To Explode
    Oilprice.com9 hours ago

    The Global Cannabis Market Is Set To Explode

    2018 saw the North American cannabis market explode, peaking when Canada announced it will fully legalize recreational use, but the opportunities for this commodity are only just beginning

  • Benzinga11 hours ago

    Benzinga's Bulls & Bears Of The Week: AbbVie, Netflix, Philip Morris, Wells Fargo And More

    Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included a leading big bank and an video streaming giant. Bearish calls included giants in tobacco and social ...

  • Analysts’ Recommendations for Stryker and Its Peers in July
    Market Realist3 days ago

    Analysts’ Recommendations for Stryker and Its Peers in July

    The SG&A expenses incurred by Stryker (SYK) are expected to increase 9.4% from $1.05 billion in the second quarter of 2017 to $1.15 billion in the second quarter. Total operating expenses incurred by Stryker are expected to reach $1.42 billion for the second quarter, compared with $1.49 billion for the second quarter of 2017. Analysts expect Stryker (SYK) to report net income of $549.25 million in the second quarter compared with $391.0 million in the second quarter of 2017, an increase of 40.47%.

  • Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?
    Zacks3 days ago

    Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?

    Gilead (GILD) is likely to beat expectations in the second quarter propelled by the momentum in the HIV franchise.

  • Analyzing AbbVie before Its Second-Quarter Earnings
    Market Realist3 days ago

    Analyzing AbbVie before Its Second-Quarter Earnings

    AbbVie (ABBV) is expected to report its second-quarter earnings on July 27. AbbVie is a global research-focused biopharmaceutical company. AbbVie makes drugs like Humira, Imbruvica, Synagis, and Creon. The company’s products treat conditions like chronic autoimmune diseases in rheumatology, gastroenterology, oncology, and hepatitis C as well as neurological disorders like Parkinson’s disease and metabolic diseases.

  • Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals
    Zacks3 days ago

    Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

    J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.

  • ACCESSWIRE3 days ago

    Today’s Research Reports on Stocks to Watch: eBay and AbbVie

    NEW YORK, NY / ACCESSWIRE / July 20, 2018 / eBay and AbbVie both saw losses in Thursday’s session. eBay dropped on dismal earnings while AbbVie dropped on a negative tweet from short seller Citron Research. ...

  • 3 Top Healthcare Stocks to Buy in July
    Motley Fool3 days ago

    3 Top Healthcare Stocks to Buy in July

    New products, bigger markets, and market-moving news could cause shares in these three companies to rally.

  • AbbVie Has Issues, But It Isn't the 'Next Big Drug Short'
    Bloomberg4 days ago

    AbbVie Has Issues, But It Isn't the 'Next Big Drug Short'

    Citron tweeted Thursday that AbbVie was “the next great drug short” and that its 12-month price target was $60. The drug is protected by a robust wall of patents that several companies have  failed to batter down.

  • Why AbbVie Shares Are Sliding Today
    InvestorPlace4 days ago

    Why AbbVie Shares Are Sliding Today

    AbbVie (NYSE:ABBV) stock took a hit today following comments concerning biosimilars.Source: Shutterstock

  • Investopedia4 days ago

    How AbbVie Makes its Money

    Devised as the research arm of Abbott and based in Chicago, AbbVie became a major pharmaceutical company in its own right in 2013. The diminished Abbott now retains the non-research interests – everything from baby formula to sports nutrition to heart stents. As for AbbVie and its separation from its progenitor, management claimed that the move gave investors a chance to objectively value two businesses that were heading in disparate directions.

  • Barrons.com4 days ago

    AbbVie's Tumble May Not Last

    The drug maker's shares are tumbling on two factors: First is the Department of Health and Human Services's proposal for the Office of Management and Budget to advance with the process of revising regulations that have allowed pharmaceutical companies to offer insurers and pharmacy-benefit managers rebates. Evercore ISI's Joshua Schimmer isn't overly worried yet.

  • Benzinga4 days ago

    AbbVie's Stock Hit By Citron Tweet

    In a speech on Wednesday, U.S. Food and Drug Administration commissioner Scott Gottlieb ripped drug makers for blocking competitors from bringing potentially cheaper biosimilar drugs to the market. On ...

  • ACCESSWIRE4 days ago

    3 Biotech Stocks to Watch This Quarter

    CORAL GABLES, FL / ACCESSWIRE / July, 19 2018 / President Trump continues to put down the pharmaceutical industry on a regular basis, despite this biotech stocks are doing well over the last year. Since ...

  • MarketWatch4 days ago

    AbbVie shares drop 5.5% after short seller Citron calls it 'next great drug short'

    AbbVie Inc. (ABBV) shares dropped 5.5% in heavy Thursday morning trade after short seller Citron Research described the company as "the next great drug short" in a tweet and said it planned to release reports about the company. The Citron tweet came the day after Food and Drug Administration Commissioner Scott Gottlieb put out a plan to encourage the development and uptake of lower-priced biosimilar drugs, accusing large drugmakers in a speech of stymying the competition. The short seller also predicted that AbbVie shares, which closed at $94.40 on Wednesday, would drop to $60.

  • Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
    Zacks4 days ago

    Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

    On the Q2 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance

  • 3 Big Stock Charts for Thursday: McDonald’s, AbbVie and Coca-Cola
    InvestorPlace4 days ago

    3 Big Stock Charts for Thursday: McDonald’s, AbbVie and Coca-Cola

    American Express Company (NYSE:AXP) was arguably the day’s biggest story, with shares up 1.8% headed into its post-close earnings report, though fell 2.7% after hours when revenue fell short of estimates. International Business Machines (NYSE:IBM) took a different path. To that end, Coca-Cola (NYSE:KO), AbbVie (NYSE:ABBV) and McDonald’s (NYSE:MCD) are lining up as Thursday’s top prospects.

  • TheStreet.com5 days ago

    3 'Strong Buy' Healthcare Stocks Poised to Surge

    Bring on healthcare earnings season. Ahead of earnings season for the group, we have selected three healthcare stocks beating the market in 2018. Using TipRanks' Stock Screener tool, we quickly discovered the best-rated stocks, filtering by "best analyst consensus" stocks in the healthcare sector.

  • Drugmakers Game the Patent System and Reap Billions, FDA Says
    Bloomberg5 days ago

    Drugmakers Game the Patent System and Reap Billions, FDA Says

    Efforts by drugmakers to thwart less-expensive rivals for pricey biologic medicines cost the U.S. health-care system billions of dollars last year, the Food and Drug Administration’s chief said in laying out a plan to end such practices. It plans to work with the Federal Trade Commission to stop “gaming tactics” like piling up patents to extend the commercial dominance of brand-name medicines, FDA Commissioner Scott Gottlieb said in a speech on Wednesday in Washington. Gottlieb said he also wants Congress’s help to close any loopholes that enable drugmakers to hinder competition from so-called biosimilars.

  • AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.
    Zacks5 days ago

    AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.

    AbbVie (ABBV) strikes a deal with Mylan to launch its biosimilar Humira in the United States on Jul 31, 2023.

  • Reuters6 days ago

    Mylan signs U.S. license deal on Humira with AbbVie

    AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition. The deal is in line with AbbVie's strategy to fend off rivals of the world's best-selling prescription drug until 2023, giving the company more time to bolster its pipeline with new cash cows to offset the expected sales decline. Humira, which treats rheumatoid arthritis, raked in $18.43 billion in sales last year and accounted for nearly two-thirds of AbbVie's net revenue.

  • PR Newswire6 days ago

    AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan

    NORTH CHICAGO, Ill., July 17, 2018 /PRNewswire/ -- AbbVie (ABBV) announced today patent license agreements with Mylan over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Mylan a non-exclusive license on specified dates to AbbVie's intellectual property relating to HUMIRA in the United States and in various other countries around the world in which AbbVie has intellectual property, excluding Europe.

  • 3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018
    Motley Fool8 days ago

    3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018

    Forget what's happened so far in 2018. These big pharma stocks look like great picks for the rest of the year.

  • AbbVie Announces Collaborations with Calico and Calibr
    Market Realist10 days ago

    AbbVie Announces Collaborations with Calico and Calibr

    Calico is a life sciences company focused on aging research and therapeutics. Together, AbbVie and Calico have produced more than two dozen early-stage programs for disease states across oncology and neuroscience since 2014. The agreement has extended the AbbVie-Calico collaboration for three years.

  • AbbVie’s Supplemental New Drug Application for Venetoclax
    Market Realist10 days ago

    AbbVie’s Supplemental New Drug Application for Venetoclax

    On July 12, AbbVie (ABBV) announced that it had submitted an sNDA (supplemental new drug application) to the FDA for venetoclax for treating newly diagnosed AML (acute myeloid leukemia) patients not eligible for intensive chemotherapy. AML is an aggressive form of cancer with very low rates of survival and few available options for patients who are ineligible for intensive chemotherapy. The FDA has granted the drug two breakthrough therapy designations for AML.